Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bioventus (BVS) EBT (2020 - 2026)

Bioventus filings provide 6 years of EBT readings, the most recent being $14.1 million for Q4 2025.

  • On a quarterly basis, EBT rose 26784.91% to $14.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $25.7 million, a 149.12% increase, with the full-year FY2025 number at $25.7 million, up 149.12% from a year prior.
  • EBT hit $14.1 million in Q4 2025 for Bioventus, up from $4.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $24.5 million in Q2 2021 to a low of -$130.6 million in Q4 2022.
  • Median EBT over the past 5 years was -$5.4 million (2024), compared with a mean of -$16.4 million.
  • Biggest five-year swings in EBT: tumbled 4043.38% in 2022 and later skyrocketed 26784.91% in 2025.
  • Bioventus' EBT stood at -$2.8 million in 2021, then crashed by 1079.64% to -$32.4 million in 2022, then skyrocketed by 74.09% to -$8.4 million in 2023, then soared by 99.37% to -$53000.0 in 2024, then skyrocketed by 26784.91% to $14.1 million in 2025.
  • The last three reported values for EBT were $14.1 million (Q4 2025), $4.7 million (Q3 2025), and $10.3 million (Q2 2025) per Business Quant data.